Antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against SARS-CoV-2 omicron...
As of November, 2024, SARS-CoV-2 omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2),1 KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC2—a recombinant lineage between KS.1.1 (JN.13.1.1.1) and...
thelancet.com